ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs MXN
16.7804
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,806.88
0.02%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Europa
  5. EU
  6. Pharming Group NV (PHARM)

  7. Pharming Group NV (PHARM) Noticias

PHARM

Pharming Group NV (PHARM)

Pharming Group NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:EU:PHARM
FechaHoraFuenteTítuloSímboloCompañía
08/05/202400:00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
24/04/202401:00GlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
24/04/202400:00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
19/04/202411:43GlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
18/04/202408:04GlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
18/04/202401:00GlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/04/202400:00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
04/04/202401:30GlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
04/04/202400:00GlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
03/04/202401:00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
14/03/202401:00GlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
29/02/202401:00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
08/02/202401:00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/01/202400:00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
13/12/202300:00GlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
21/11/202300:00GlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
10/11/202307:51GlobeNewswire Inc.Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalEU:PHARMPharming Group NV
01/11/202302:00GlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
26/10/202300:00GlobeNewswire Inc.Pharming Group reports third quarter 2023 financial resultsEU:PHARMPharming Group NV
12/10/202301:00GlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
25/09/202309:00GlobeNewswire Inc.Pharming Group reports on results of the 2023 Extraordinary General Meeting of ShareholdersEU:PHARMPharming Group NV
24/03/202318:22Dow Jones NewsADRs End Mostly Lower, Pharming Group Trades ActivelyEU:PHARMPharming Group NV
13/03/202303:34Dow Jones NewsPharming Expects to Have Access to $26 Million It Has on Deposit at SVB USEU:PHARMPharming Group NV
23/12/202104:02Dow Jones NewsPharming Group, Sanofi Renew Strategic Manufacturing Partnership AgreementEU:PHARMPharming Group NV
01/07/202100:00GlobeNewswire Inc.Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Thera...EU:PHARMPharming Group NV
09/08/201606:20Dow Jones NewsValeant Posts a Loss, Says It Will RetoolEU:PHARMPharming Group NV
06/03/201400:13GlobeNewswire Inc.Pharming Reports On Preliminary Financial Results 2013EU:PHARMPharming Group NV
24/02/201400:12GlobeNewswire Inc.PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)EU:PHARMPharming Group NV
08/11/201300:06GlobeNewswire Inc.PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE I...EU:PHARMPharming Group NV
07/11/201300:10GlobeNewswire Inc.Pharming Reports On Financial Results For The First Nine Months Of 2013EU:PHARMPharming Group NV
 Showing the most relevant articles for your search:EU:PHARM

Su Consulta Reciente

LATK
SCTETH
Soma Community
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados